Clinical trials have demonstrated that Eli Lilly’s anti-SARS-CoV-2 drug is unlikely to improve health outcomes. Enrollment in the trial was paused by the NIH paused following a review by an independent data safety monitoring board – there was very little difference between LY-CoV555 and a placebo. Despite this result, the U.S. government has agreed to pay $375 million for 300,000 doses of the drug as the company has noted that it may work better in earlier stage patients. Yourway supports the full scope of the clinical supply chain by combining years of experience, unrivaled responsiveness, and our global network of GMP depots.